Abstract: This invention describes a method for in vitro production of a population of human hemogenic endothelial cells (HECs), preferably further differentiated to hematopoietic stem cells (HSC). Particularly the method relates to a method of differentiating pluripotent stem cell aggregates to hemogenic endothelial cell (HEC) aggregates, and further differentiating the hemogenic endothelial cell aggregates to hematopoietic stem cell (HSC) aggregates, wherein the step of differentiating PSCs to HECs comprises a step of culturing the cells with BMP4 and a step of culturing the cells without BMP4. The invention also relates to populations of human HSCs or cryopreserved HSCs, as well as a culture medium or a bioreactor with culture medium comprising the cells or population of cells.

Abstract: The present application relates to the field of immunotherapy, more particularly to the manufacture of cells for adoptive cell therapy. Provided herein are methods to prevent and/or reduce fratricide during manufacturing of such cells, particularly of cells expressing a chimeric NKG2D receptor. Also provided are cells and compositions comprising cells in which fratricide is prevented and/or reduced.

Abstract: The present application relates to the field of immunotherapy, more particularly to the manufacture of cells for adoptive cell therapy. Provided herein are methods to prevent and/or reduce fratricide during manufacturing of such cells, particularly of cells expressing a chimeric NKG2D receptor. Also provided are cells and compositions comprising cells in which fratricide is prevented and/or reduced.

Abstract: A cell processing device is provided that is suitable for performing independent concurrent processing of a plurality of cell preparations, the cell processing device comprising: (I) a cell processing station; and (II) a plurality of cell processing modules, wherein the plurality of cell processing modules engage and communicate with the cell processing station; wherein each of the plurality of cell processing modules comprises discrete processing compartments defined within, the processing compartments comprising: (i) a reagent pack, the reagent pack comprising one or more reagent vessels; d (ii) one or more fluidic cartridges, each fluidic cartridge comprising one or more cell processing compartments and a cell incubation compartment, wherein each of the processing compartments is in fluid communication with each other.

Abstract: The present application relates to the field of immunotherapy, more particularly to the manufacture of cells for adoptive cell therapy. Provided herein are methods to prevent and/or reduce fratricide during manufacturing of such cells, particularly of cells expressing a chimeric NKG2D receptor. Also provided are cells and compositions comprising cells in which fratricide is prevented and/or reduced.